US 11,739,132 B2
Separation moieties and methods of use thereof
William Winston, West Newton, MA (US); Luke Evnin, San Francisco, CA (US); Vinay Bhaskar, San Francisco, CA (US); Giselle Knudsen, San Anselmo, CA (US); Daniel J. Hicklin, Boston, MA (US); Cynthia Seidel-Dugan, Belmont, MA (US); Jose Andres Salmeron Garcia, Acton, MA (US); and Heather R. Brodkin, West Newton, MA (US)
Assigned to Werewolf Therapeutics, Inc., Watertown, MA (US)
Filed by Werewolf Therapeutics, Inc., Cambridge, MA (US)
Filed on Feb. 22, 2022, as Appl. No. 17/677,473.
Application 17/677,473 is a continuation of application No. 17/082,955, filed on Oct. 28, 2020.
Application 17/082,955 is a continuation of application No. PCT/US2020/032988, filed on May 14, 2020.
Claims priority of provisional application 62/938,786, filed on Nov. 21, 2019.
Claims priority of provisional application 62/847,914, filed on May 14, 2019.
Prior Publication US 2022/0220181 A1, Jul. 14, 2022
Int. Cl. C07K 14/715 (2006.01); C07K 14/55 (2006.01); C07K 16/28 (2006.01); C07K 14/57 (2006.01); A61K 39/00 (2006.01); A61K 47/64 (2017.01); C07K 14/52 (2006.01)
CPC C07K 14/55 (2013.01) [C07K 14/57 (2013.01); C07K 14/7155 (2013.01); C07K 16/2887 (2013.01); A61K 47/642 (2017.08); A61K 2039/505 (2013.01); C07K 14/52 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01); C07K 2319/33 (2013.01); C07K 2319/50 (2013.01); C07K 2319/70 (2013.01)] 16 Claims
 
1. A recombinant pro-protein comprising:
a. a recombinant polypeptide comprising, a cleavable moiety that is a substrate for a protease, wherein the cleavable moiety comprises the amino acid sequence of SEQ ID NO: 198 or a functional variant of SEQ ID NO: 198 in which one or two amino acids are substituted in SEQ ID NO: 198; and
b. a polypeptide with biological activity.